ASX-listed Neurotech International has announced the expansion of its exclusive licence with Dolce Cann Global to include all neurological disorders, specifically autism, epilepsy, ADHD, alzheimer’s disease, huntington’s disease, multiple sclerosis, transverse myelitis, inflammatory brain disease, fibromyalgia, chronic fatigue and migraine.
Neurotech said latest clinical research shows inflammation, and more specifically neuroinflammation, is a well-recognised common feature in all neurological disorders.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.